Versatile & Neutral Taste Blends seamlessly into shakes, smoothies, and recipes without altering flavour, perfect for daily use
For CKD stages 35 (non-dialysis), the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines typically recommend 0.550.60 g/kg/day (0.60.8 g/kg in diabetes)
The GLP-1 space is not just growingits redefining metabolic disease management worldwide
Semaglutide was originally developed for managing type 2 diabetes under brand names such as Ozempic and Rybelsus, and later received FDA approval for chronic weight management under the brand name Wegovy
Functional Performance Profile Key Benefits Triple Agonist: GLP-1, GIP & Glucagon Advanced Weight Loss Muscle Preservation Metabolic Optimisation Improved Energy & Focus Product Specifications Purity: 99.8% Form: Lyophilized peptide Storage: 2-9C Refrigerated Research Information Type: Triple receptor agonist Pathways: GLP-1 / GIP / Glucagon Focus: Metabolic regulation Scientific Information Research Reference Parameters Laboratory Use Only Initial phase: 2-4 mg once weekly Standard research range: 5-8 mg once weekly Advanced research range: 8-12 mg once weekly Research cycles typically extend 8-16 weeks Mechanism of Action Retatrutide functions as a triple agonist: GIP activation enhances insulin secretion and fat metabolism
How much is it without insurance